Skip to main navigation Molecular Partners About Us DARPin Biology The DARPin Platform Pipeline Investors SCIENTIFIC 2021 2020 2019 2018 2017 2016 2015 EVENT PUBLICATION DOCUMENT ISIRV-WHO 2021 conference EMPATHY: A Ph2 3 Randomized, Placebo Controlled Trial Evaluating Safety and Efficacy of Ensovibep in Ambulatory COVID 19 Patients 18th CIMT Annual Meeting CD3-slow release DARPin® (CD3-SRD) concept – a smart solution for reducing cytokine release syndrome while maintaining optimal anti-tumor efficacy AACR 2021 MP0317: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo AACR 2021 pMHC: Application of the DARPin® technology for specific targeting of tumor-associated MHC class I:peptide complexes AACR 2021 Prodrug: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model AACR 2021 AML: Immunomodulatory Agents and Interventions INVESTORS > SIDEBAR MENU Overview News & Events Scientific Documents Stock Information Corporate Governance Financials & Filings General Meeting IR Resources > Footer Menu COOKIE NOTICE PRIVACY & DISCLAIMER CONTACT US > Footer Social © 2021 Molecular Partners.

Skip to main navigation Molecular Partners About Us DARPin Biology The DARPin Platform Pipeline Investors DOCUMENTS & CHARTERS GOVERNANCE DOCUMENTS Code of Conduct Articles of Incorporation Organizational Rules Anti-Corruption Policy COMMITTEE CHARTERS Charter of the Audit and Finance Committee Charter of the Research and Development Committee Charter of the Nomination and Compensation Committee INVESTORS > SIDEBAR MENU Overview News & Events Scientific Documents Stock Information Corporate Governance Documents & Charters Management Team & Board of Directors Committee Composition Major Shareholders Management Transactions Financials & Filings General Meeting IR Resources > Footer Menu COOKIE NOTICE PRIVACY & DISCLAIMER CONTACT US > Footer Social © 2021 Molecular Partners.